TuHURA Biosciences, Inc./NV

Listed Company

HURACIK 0001498382NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsNevadaFY ends Dec 31

Period

FY 2025

Revenue

Net Income

$-30.05M

Total Assets

—

Equity

—

Shares Out

63.68M

Op. Cash Flow

$-27.63M

Business

TuHURA Biosciences, Inc./NV is a clinical-stage immuno-oncology company developing technologies to overcome primary and acquired resistance to cancer immunotherapies. It is developing innate immune agonists (including IFx-2.0 for intratumoral pDNA delivery and IFx-3.0 mRNA candidates) and tumor microenvironment modulators such as bi‑specific antibody‑peptide conjugates (APCs) and antibody‑drug conjugates (ADCs) targeting MDSCs via Delta Opioid Receptor technology. Its key business activities are clinical development, platform R&D and licensed Delta Receptor programs. The company pursues U.S. regulatory pathways and global clinical collaborations, leveraging CDMOs and development partnerships for distribution and manufacturing.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2024 2024-06-30	FY 2023 2023-12-31	FY 2023 2023-06-30
Research and development expenses	21	13	3	9	9
Acquisition-related costs (note 5)	4	440,340	—	—	—
General and administrative expenses	8	4	6	4	5
Operating Loss	−32	−18	−8	−30	−15
Employee Retention Tax Credit	113,574	—	—	334,443	—
Grant income	713,508	57,627	—	42,466	—
Interest expense	−625,283	−4	—	−18,688	—
Interest income	136,233	361,632	—	89,673	—
Change in fair value of derivative liability	—	−313,772	—	—	—
Change in fair value of Kineta merger holdback shares	2	—	—	—	—
Loss on Kineta employee separation payments assumed from merger	−185,019	—	—	—	—
Total Other Income (Expense)	2	−4	—	447,894	—
Net Loss	−30	−22	−8	−29	−15
Series A Preferred cash dividend	−8,356	−2,089	−8,000	—	−8,000
Deemed dividend on warrant modifications	0	−965,177	—	—	—
Net Loss attributable to common stockholders	−30	−23	−9	−29	−15
Net Loss per share, basic	−0.63	−1.21	−0.32	−2.47	−9.27
Net Loss per share, diluted	−0.63	−1.21	—	−2.47	—
Weighted-average shares outstanding, basic	48	19	26	12	2
Weighted-average shares outstanding, diluted	48	19	—	12	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2024 2024-06-30	FY 2023 2023-12-31	FY 2023 2023-06-30
Cash and cash equivalents	4	13	5	4	2
Deposits, planned business acquisition (note 1)	—	6	—	—	—
Stock Subscription Receivable	500,000	—	—	—	—
Other current assets	501,187	958,708	—	493,769	—
Total Current Assets	5	20	6	4	3
Property and equipment, net	300,639	123,366	674,000	182,170	709,000
Operating right-of-use assets	384,530	199,160	—	20,820	—
Other noncurrent assets	33,769	33,769	—	—	—
Goodwill	11	—	—	—	—
In-process research and development	11	—	—	—	—
Total Assets	27	20	6	4	4
Accounts payable and accrued expenses	6	5	2	3	3
Kineta severance promissory notes	197,354	—	—	—	—
Lease liabilities, current	199,041	159,844	—	20,820	—
Total Current Liabilities	6	5	2	4	3
Lease liability, long term	303,627	42,698	—	—	—
Deferred tax liability	197,919	—	—	—	—
Total Liabilities	6	5	2	6	3
Commitments and contingencies (note 14)	—	—	—	—	—
Common stock, $0.001 par value, 200,000,000 and 75,000,000 shares authorized as of December 31, 2025 and 2024; 59,336,104 and 12,167,679 shares issued and outstanding as of December 31, 2025 and 2024.	59,336	42,324	55,000	12,168	2,000
Additional paid-in capital	162	125	153	87	141
Accumulated deficit	−141	−111	−160	−88	−151
Total Stockholders' Equity	21	15	4	−2	731,000
Total Liabilities and Stockholders' Equity (Deficit)	27	20	6	4	4

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2024 2024-06-30	FY 2023 2023-12-31	FY 2023 2023-06-30
Net loss	−30	−22	—	—	—
Stock compensation expense	6	2	—	478,890	—
Depreciation and amortization	71,265	116,710	—	177,377	—
Amortization of debt discount	481,424	1	—	5,124	—
Loss on share issuance to Kineta separation payments	185,019	—	—	—	—
Change in fair value of holdback shares	−2	—	—	—	—
Change in fair value of derivative liability	—	313,772	—	—	—
Other current assets	457,523	−464,938	—	−1,995	—
Other noncurrent assets	154,998	106,613	—	151,173	—
Accounts payable and accrued expenses	−4	4	−577,000	337,746	−442,000
Net cash flows from operating activities	−28	−15	−7	−12	−12
Cash paid for Kineta acquisition, net of assumed cash	−1	−6	—	—	—
Purchase of property and equipment	−76,083	−57,906	—	−79,224	—
Net cash flows from investing activities	−1	−6	−20,000	−1	−232,000
Series A Preferred dividend	−8,356	—	−6,000	—	−8,000
Repayment of assumed Kineta indeptedness	−434,000	—	—	—	—
Payments made on Kineta severance promissory notes	−394,709	—	—	—	—
Payments on equipment lease	−54,315	—	—	—	—
Proceeds from convertible notes payable	—	29	—	3	—
Proceeds from bridge note	3	—	—	—	—
Payment of bridge note	−2	—	—	—	—
Proceeds from issuance of common stock	18	5	—	—	—
Proceeds from stock options exercised	—	104,000	—	—	—
Proceeds from warrants exercised	4	2	—	—	—
Payment of offering costs associated with issuance of common stock	−2	−300,000	—	—	−43,000
Payment of merger transaction costs	−500,000	−4	—	—	—
Payment of debt issuance costs	—	−1	—	—	—
Payment of net liabilities assumed in reverse recapitalization	−550,000	−796,912	—	—	—
Net cash flows from financing activities	20	30	11	3	2
Net change in cash and cash equivalents	−9	9	3	−11	−10
Cash paid for interest	59,364	—	—	—	—
Right-of-use asset recognized in exchange for operating lease obligations	340,368	318,722	—	—	—
Right-of-use asset recognized in exchange for finance lease obligations	172,453	—	—	—	—
Deferred offering costs not yet paid	463,903	—	—	—	—
Consideration for Kineta acquisition issued in shares	9	—	—	—	—
Net liabilities assumed in reverse recapitalization not yet paid	—	550,000	—	—	—
Merger transaction costs not yet paid	—	500,000	—	—	—
Derivative liability associated with make-whole premium	—	2	—	137,000	—
Warrants issued recorded as a debt discount	301,424	7	—	—	—
Shares issued for placement agent fees	—	443,560	—	—	—
Contingent value rights associated with Kintara merger	—	5	—	—	—
Warrants issued to financial advisor	—	2	—	—	—
Shares issued for payment of bridge note	2	—	—	—	—
Shares issued upon settlement of convertible notes	—	28	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro